TY - JOUR
T1 - Natural history of the revised ALS functional rating scale and its association with survival
T2 - the PRECISION-ALS Extant Study
AU - van Eijk, Ruben P A
AU - Weemering, Daphne N
AU - Opie-Martin, Sarah
AU - van Unnik, Jordi W J
AU - Caravaca Puchades, Alejandro
AU - Chiò, Adriano
AU - Corcia, Philippe
AU - Galvin, Miriam
AU - Hardiman, Orla
AU - Heverin, Mark
AU - Hobin, Frederik
AU - Holmdahl, Oskar
AU - Ingre, Caroline
AU - Lamaire, Nikita
AU - Mac Domhnaill, Éanna
AU - McDonough, Harry
AU - Manera, Umberto
AU - McDermott, Christopher J
AU - McFarlane, Robert
AU - Mouzouri, Mohammed
AU - Ombelet, Fouke
AU - Povedano Panadés, Mónica
AU - Sennfält, Stefan
AU - Shaw, Pamela J
AU - Terrafeta Pastor, Cristina
AU - Van Damme, Philip
AU - Vasta, Rosario
AU - Veldink, Jan H
AU - Al-Chalabi, Ammar
AU - van den Berg, Leonard H
N1 - Publisher Copyright:
© 2024 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.
PY - 2025/5
Y1 - 2025/5
N2 - Objective: To characterize the natural history of the revised ALS functional rating scale (ALSFRS-R) over a 24-month period following initial assessment, and to assess its associations with survival. Methods: Longitudinal ALSFRS-R measurements and survival data were obtained from seven population-based, European cohorts. Different models for the ALSFRS-R trajectory were evaluated, including tests for linearity and between-cohort differences. We employed a joint modeling framework to factor in mortality, thereby aiming to derive a more precise estimate of the population’s rate of decline, while simultaneously delineating its relationship with survival. Results: In total, 7,030 patients were included who produced 31,746 ALSFRS-R measurements during a follow-up period of 10,285 person-years. There was substantial evidence for a non-linear time trend within all cohorts (all p < 0.001), with faster progression rates at the beginning of follow-up. The average rate over 24 months was 0.89 points per month; 95% of the patients had a rate between 0.04 and 1.96. Overall, two components of the ALSFRS-R trajectory were found to be associated with survival: (1) the actual value of the ALSFRS-R total score and (2) the rate of change at any given time (both p < 0.001). Conclusions: Functional loss in ALS follows a decelerating trajectory, where the current functional status and the rate of change have a direct impact on the patient’ s probability of survival. Given the pivotal role of the ALSFRS-R in drug development, these results help to separate treatment benefit from the disease’s natural trajectory and to estimate the impact on survival.
AB - Objective: To characterize the natural history of the revised ALS functional rating scale (ALSFRS-R) over a 24-month period following initial assessment, and to assess its associations with survival. Methods: Longitudinal ALSFRS-R measurements and survival data were obtained from seven population-based, European cohorts. Different models for the ALSFRS-R trajectory were evaluated, including tests for linearity and between-cohort differences. We employed a joint modeling framework to factor in mortality, thereby aiming to derive a more precise estimate of the population’s rate of decline, while simultaneously delineating its relationship with survival. Results: In total, 7,030 patients were included who produced 31,746 ALSFRS-R measurements during a follow-up period of 10,285 person-years. There was substantial evidence for a non-linear time trend within all cohorts (all p < 0.001), with faster progression rates at the beginning of follow-up. The average rate over 24 months was 0.89 points per month; 95% of the patients had a rate between 0.04 and 1.96. Overall, two components of the ALSFRS-R trajectory were found to be associated with survival: (1) the actual value of the ALSFRS-R total score and (2) the rate of change at any given time (both p < 0.001). Conclusions: Functional loss in ALS follows a decelerating trajectory, where the current functional status and the rate of change have a direct impact on the patient’ s probability of survival. Given the pivotal role of the ALSFRS-R in drug development, these results help to separate treatment benefit from the disease’s natural trajectory and to estimate the impact on survival.
KW - Adult
KW - Aged
KW - Amyotrophic Lateral Sclerosis/mortality
KW - Cohort Studies
KW - Disease Progression
KW - Female
KW - Humans
KW - Longitudinal Studies
KW - Male
KW - Middle Aged
KW - Severity of Illness Index
KW - Survival Rate/trends
U2 - 10.1080/21678421.2024.2443985
DO - 10.1080/21678421.2024.2443985
M3 - Article
C2 - 40326917
SN - 2167-8421
VL - 26
SP - 30
EP - 40
JO - Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
IS - sup1
ER -